Arylamide CFTR Modulators for NBD1 Stabilization in Cystic Fibrosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is no cure for cystic fibrosis, and existing treatments for CFTR-mediated conditions are inadequate, with the most common mutation (AF508) causing misfolded CFTR protein that disrupts ionic homeostasis and leads to chronic lung infections and organ dysfunction.
Innovation Solution
Development of arylamide compounds that can augment CFTR activity by stabilizing the NBD1 domain, potentially restoring channel function and improving ionic homeostasis, thereby treating conditions associated with deficient CFTR activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule CFTR modulators are used to increase CFTR channel function, then CFTR activity is improved, but no complete cure is achieved and disease severity persists
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of CFTR modulators through Formula (I) compounds with specific substituent patterns (R1-R7, Z1-Z6, A-B-C-D-E parameters). These structural parameter changes aim to enhance binding affinity and functional efficacy beyond existing modulators, transforming the therapeutic outcome from partial improvement to potential cure.
2Reliability
If compounds of Formula (I) are developed to augment CFTR activity, then channel function is enhanced, but complexity of compound structure increases
Solution Approach 1:
The patent applies segmentation by dividing the complex molecule into distinct functional domains represented by variables A through E and substituents R1-R7. Each domain can be independently optimized and synthesized, allowing systematic development of complex structures through modular assembly of well-characterized building blocks.
Solution Approach 2:
The patent systematically varies structural parameters (different aryl/heteroaryl groups for E, various alkyl chains for R groups, different heteroatom patterns for Z) to optimize CFTR binding and function. This parameter exploration allows identification of high-efficacy compounds while maintaining synthetic accessibility through defined structural classes.
3Adaptability or versatility
If new compounds are identified to treat cystic fibrosis, then therapeutic options are expanded, but time and resources for identification and development are increased
Solution Approach 1:
The patent performs preliminary action by pre-defining a comprehensive chemical space through Formula (I) with systematically varied substituents before biological testing. This pre-organized library approach allows parallel screening of multiple candidates with predicted different mechanisms of action, accelerating identification of effective compounds compared to random screening.
Solution Approach 2:
The patent creates universal compounds through Formula (I) that may address multiple aspects of CFTR dysfunction simultaneously (folding, trafficking, gating). The modular structure allows single compounds to potentially correct multiple defect types, reducing the number of compounds needed to be tested across different mutation types.
Data Source
AI summary
The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.